PDX Pharmaceuticals is a biopharmaceutical company leveraging novel nanotechnology and cancer systems biology to develop next-generation combination immunotherapies for cancer. We aspire to substantially improve health care using our nanotechnology platforms. PDX Pharma was established in 2010, supported by the Biomedical Engineering Department of Oregon Health and Science University (OHSU) School of Medicine and The Oregon Nanoscience and Microtechnologies Institute (ONAMI). 

Our proprietary nanoparticle platform (Pdx-NP™) can co-deliver siRNA, chemo drugs, vaccines, and/or immunotherapies and it is capable of targeted delivery of these cargos to solid tumors upon intravenous administration. We capitalize on this platform to generate next generation combination immune therapies for cancer by co-delivering therapeutics targeting complementary cancer and immune pathways, leading to synergistic clinical benefits. Our therapeutic candidates have been shown to overcome resistance of current targeted therapies and trigger antitumor immune response in animal models. 

Our strategy is to build significant value in our therapeutic candidates that address unmet medical need and have substantial commercial potential, secure intellectual property rights, and initiate early stage commercial development. We are conducting IND enabling studies of two drug candidates (AIRISE-02 and ARAC-02) funded by the National Cancer Institute (NCI) and are raising additional private investment to complete their clinical trials by 2025.

Our technologies have been developed through support from NIH (NCI, NCATS, NIDDK, NIGMS, NIEHS, NIAID), ONAMI, OHSU, PNNL, and Foundations (Prospect Creek, Wayne D. Kuni & Joan E. Kuni, Gordon Moore, Hillcrest, Women’s Health Circle of Giving).